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The dermatology education series: A digital approach to
improving patient engagement
Cassandra Yeboah, BS, MBS, Philadelphia College of Osteopathic
Medicne; Alaina James, MD, PhD, University of Pittsburgh
Department of Dermatology
Dermatology is unique in that not only are there a shortage of dermatologists in the
United States but patient access care to is largely disproportionate. As a response to
the chasm of access that exists, many patients have relied on the Internet to obtain
information on how to address their concerns, and this often comes at the cost of
non-evidence based remedies being promoted. The inception of the 2020 COVID-19
pandemic has led many physicians to restrategize their approach to patient care.
Fortunately, utilization of a virtual model has been integral to this process. The
purpose of this study was twofold: increase patient confidence in addressing
dermatologic concerns by providing targeted education on specific dermatologic
topics and define a framework that can be implemented by dermatologists looking
to use social media to increase patient education and access to dermatologic care. 3
separate education sessions (webinars) were held where the topics of hair, eczema,
and acne were discussed, respectively. Each session was roughly 1 hour in length.
Attendees were given pre- and postwebinar surveys to assess existing patient
attitude toward their knowledge of dermatologic topics and their comfort in
consulting a dermatologist with their concerns. Across the 3-day series, the total
number of registrants was 30. 12 registrants for the hair webinar with an overall
attendance rate of 33%; 12 registrants for the eczema webinar with an overall
attendance rate of 33%; 6 registrants for the acne webinar with an overall attendance
rate of 50%.
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Jake Besch-Stokes, BS, Mayo Clinic Alix School of Medicine; Puneet Bhullar, BS,
Department of Dermatology, Mayo Clinic Arizona; Blake Boudreaux, MD,
Department of Dermatology, Mayo Clinic Arizona; Pranav Puri, BS, Mayo Clinic
Alix School of Medicine; Kevin Severson, MD, Department of Dermatology, Mayo
Clinic Arizona; Matthew Buras, MS, Division of Biostatistics, Department of
Health Science Research, Mayo Clinic, Scottsdale, AZ; Collin Costello, MD,
Department of Dermatology, Mayo Clinic Arizona; Helen Cumsky, MD,
Department of Dermatology, Mayo Clinic Arizona; Aaron Mangold, MD,
Department of Dermatology, Mayo Clinic Arizona
There is a paucity of literature comparing the bodily distribution of melanocytic nevi
vs. melanoma and racial differences in melanoma distribution. We conducted a
cross-sectional study of 211 patients who presented for voluntary skin examination
from 3/2017-8/2018. Demographic data were obtained before the examination.
Nevi were verified by dermoscopy and mapped by location. Data were compared
with 2000-2017 melanoma data reported by the Surveillance, Epidemiology, and End
Results (SEER) program. Patients self-identified as Hispanic (64.9%), Caucasian
(19.2%), American Indian or Alaskan Native (7.2%), Asian (1.9%), and other (1.4%).
The greatest differences in distribution of nevi and melanoma were observed at the
lower limb/hip (17.3% of melanomas vs. 6.6% of nevi; P \.0001), upper limb and
shoulder (26% of melanomas vs. 34.1% of nevi), foot (0.8% of melanomas vs. 2.8% of
nevi), and hand (0.2% of melanomas vs. 2.6% of nevi). Caucasians had higher
incidence (per 100,000) of melanomas of the face/neck (4,400; 95% CI 3,700-5,100;
P \.0001), trunk (9,200; 95% CI 8,500-9,800), and upper extremity (6,800; 95 % CI
6,100-7,500) vs. skin of color (SOC) patients. SOC patients had higher incidence of
melanomas of the lower extremity (11,000; 95 % CI 10,000-11,000), acral locations
(6,800; 95% CI 5,600-8,000), and feet (5,900; 95% CI 5,100-6,500). Distribution of
nevi differed significantly from melanoma by body region. Caucasians had higher
incidence of upper-body melanomas while SOC patients had higher incidence of
lower-body and acral melanomas. These differences suggest divergent evolutionary
pathways of nevi and melanoma in various body regions and across different races.
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Background: No keloid-specific outcome measures exist.
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palmaris et plantaris
Seol Hwa Seong, MD, Department of Dermatology, Kosin University
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Methods: Forty-seven physicians were polled to develop the DKS. The scale was
validated in 52 patients with keloids against the Vancouver Scar Scale (VSS), Patient
and Observer Scar Assessment Scale (POSAS), and Dermatology Life Quality Index
(DLQI) by 3 physicians.

Background: Mycosis fungoides palmaris et plantaris (MFPP) is a variant of mycosis
fungoides (MF) that presents primarily on the palms and soles, which is often
refractory to conventional therapy. Alitretinoin is an endogenous panagonist
binding to retinoid receptors and promoting the anti-proliferative, immunemodulating, and pro-apoptotic effects. From this perspective, oral alitretinoin may
be effective to MFPP as in the MF, however, there is no previous case study. We
present a retrospective review of MFPP treated with oral alitretinoin.

Results: The interrater reliability was ‘‘substantial’’ for observer component of the
DKS and only ‘‘moderate’’ for the VSS and observer POSAS (ICC were 0.80, 0.60, and
0.47, respectively). Pearson’s correlation indicated a ‘‘moderate’’ association between the observer component of DKS with observer component of POSAS (r ¼
0.56, P \.001) and a ‘‘substantial’’ relationship between the observer component of
DKS and VSS (r ¼ 0.63, P \.001). Pearson’s correlation indicated a ‘‘moderate’’
association between the patient portion of DKS and patient portion of POSAS and
the patient portion of the DKS and DLQI (0.61 and 0.60, respectively, P \.05). The
DKS total score consistently showed ‘‘substantial’’ relationship with POSAS total
score (r ¼ 0.65, P \.001).
Limitations: Single center study, no intrarater reliability analysis.

Objective: To investigate the efficacy and safety of oral alitretinoin in MFPP.
Methods: This study was conducted on 10 patients histopathologically diagnosed as
MFPP. The patients were treated with oral alitretinoin (30 mg/day). The therapeutic
efficacy was assessed according to Physician’s Global Assessment (PGA) and
modified total lesion symptom score (mTLSS) at baseline and after 12 weeks.
Results: The proportion of clinical response defined as PGA of clear or almost clear
was 70% (7/10). The mean mTLSS was significantly decreased from 10.5 (baseline)
to 3.2 (after 12 weeks), representing a 69.5% of reduction. Half of the patients
experienced side effects such as headache (20%), elevated serum triglyceride (20%),
and dry mouth (10%), however, there were no serious events leading to withdrawal.

Conclusions: The substantial interrater reliability of the DKS will allow for improved
standardization in future keloid research.

Conclusion: Oral alitretinoin can be a well-tolerated and effective alternative
treatment for MFPP.
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Objective: To develop and validate the Detroit Keloid Scale (DKS), a standardized
method of keloid assessment to better compare treatments.
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